Literature DB >> 17561768

Streptococcus viridans has a leading role in rhinosinusitis complications.

Siew Yoong Hwang1, Kun Kiaang Tan.   

Abstract

OBJECTIVES: We sought to determine whether the bacteria in complicated rhinosinusitis were the typical acute rhinosinusitis triad of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. We also compared the difference in yield between infection sites and blood cultures.
METHODS: We performed a retrospective review of all patients who had required surgical intervention for rhinosinusitis complications over 7 years at a tertiary care pediatric hospital.
RESULTS: There were a total of 28 patients during the review period. Twenty-five organisms were isolated from 21 patients, of which Streptococcus viridans formed 44% of the isolates (11 of the 25). The typical triad of bacteria only formed 20% of the isolates (5 of the 25), and none of these bacteria were found in the group with intracranial complications. Infection site cultures had a superior yield compared to blood cultures (p < .001). Ninety-six percent of the bacteria were sensitive to a combination of amoxicillin-clavulanate and cloxacillin.
CONCLUSIONS: In distinction to the typical bacteria of acute rhinosinusitis, S. viridans is the leading cause of rhinosinusitis complications. It is not merely a commensal organism of the upper respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561768     DOI: 10.1177/000348940711600511

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

1.  Incidence and Clinical Outcomes of Streptococcus anginosus in Acute Complicated Sinusitis: A Pediatric Cohort.

Authors:  Elizabeth Troy; Stefan Sillau; Timothy J Bernard; Suchitra Rao
Journal:  J Pediatric Infect Dis Soc       Date:  2021-03-26       Impact factor: 3.164

Review 2.  Acute rhinosinusitis in children.

Authors:  Cheryl C Nocon; Fuad M Baroody
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.